Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cleara Biotech B V manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action in the portfolio, which is being handled by 1 distinct examiner. BEANE, RANDALL L is the busiest examiner with 1 pending office action. The portfolio's pending work is located in 1 distinct art unit.
This alignment of 1 pending office action, 1 distinct examiner, and 1 distinct art unit suggests a highly specific prosecution focus. Practitioners should note the centralized nature of the current review process for this biotechnology portfolio. With 1 pending office action total, the portfolio's current administrative footprint is minimal and highly localized. This structure allows for a direct relationship with the assigned examiner for the pending matter, ensuring that all current patent office interactions are filtered through 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18394683 | ANTI-SENESCENCE COMPOUNDS AND USES FOR THE TREATMENT OF CANCER | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18394683 | ANTI-SENESCENCE COMPOUNDS AND USES FOR THE TREATMENT OF CANCER | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18394683 | ANTI-SENESCENCE COMPOUNDS AND USES FOR THE TREATMENT OF CANCER | BEANE, RANDALL L | 1654 | §102§112Other | Non-Final OA | — | Pending | Dec 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial